202 related articles for article (PubMed ID: 37492437)
1. The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors.
Sampietro M; Cassina V; Salerno D; Barbaglio F; Buglione E; Marrano CA; Campanile R; Scarfò L; Biedenweg D; Fregin B; Zamai M; Díaz Torres A; Labrador Cantarero V; Ghia P; Otto O; Mantegazza F; Caiolfa VR; Scielzo C
Hemasphere; 2023 Aug; 7(8):e931. PubMed ID: 37492437
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
3. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
4. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
Sinha S; Boysen J; Nelson M; Secreto C; Warner SL; Bearss DJ; Lesnick C; Shanafelt TD; Kay NE; Ghosh AK
Clin Cancer Res; 2015 May; 21(9):2115-26. PubMed ID: 25673699
[TBL] [Abstract][Full Text] [Related]
5. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
[TBL] [Abstract][Full Text] [Related]
6. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
8. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
[TBL] [Abstract][Full Text] [Related]
9. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
10. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
11. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
St-Pierre F; Ma S
Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
[TBL] [Abstract][Full Text] [Related]
12. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
Dias AL; Jain D
Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.
Kil LP; de Bruijn MJ; van Hulst JA; Langerak AW; Yuvaraj S; Hendriks RW
Am J Blood Res; 2013; 3(1):71-83. PubMed ID: 23359016
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
Bose P; Gandhi VV; Keating MJ
Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1381-1392. PubMed ID: 27686109
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib treatment improves T cell number and function in CLL patients.
Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
Aslan B; Kismali G; Chen LS; Iles LR; Mahendra M; Peoples M; Gagea M; Fowlkes NW; Zheng X; Wang J; Vellano CP; Marszalek JR; Bertilaccio MTS; Gandhi V
Blood Adv; 2021 Aug; 5(16):3134-3146. PubMed ID: 34424317
[TBL] [Abstract][Full Text] [Related]
18. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
[TBL] [Abstract][Full Text] [Related]
19. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
Shorer Arbel Y; Katz BZ; Gabizon R; Shraga A; Bronstein Y; Kamdjou T; Globerson Levin A; Perry C; Avivi I; London N; Herishanu Y
Front Oncol; 2021; 11():646971. PubMed ID: 34055615
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Kaur V; Swami A
Ann Hematol; 2017 Jul; 96(7):1175-1184. PubMed ID: 28342031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
